Alfentanil Protein Binding in Uraemia — SCE Palliative Medicine MCQ

Instant feedback + full explanation. One question, done properly.

HardSyringe Driver & Drug CompatibilityAlfentanil Protein Binding in UraemiaSCE Palliative Medicine

A patient with severe renal failure (eGFR 8 ml/min) requires opioid analgesia via a continuous subcutaneous infusion (CSCI), and alfentanil is chosen. Which of the following monitoring strategies is most important in this setting?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Monitor sedation and respiratory depression closely

In severe renal failure, alfentanil remains the opioid of choice as it undergoes hepatic metabolism and has negligible active metabolites; dose reduction is not routinely required in CKD stage 4–5 ([rightdecisions.scot.nhs.uk](https://www.rightdecisions.scot.nhs.uk/scottish-palliative-care-guidelines/scottish-palliative-care-guidelines/medicines/medicines-information/alfentanil/?UNLID=32174904020237316748&utm_source=openai)). However, uraemia causes a rise in its free (unbound) fraction—from ~10–11 % to ~12–19 %—enhancing pharmacodynamic effects like sedation or respiratory depression ([medicines.org.uk](https://www.medicines.org.uk/emc/product/6427/smpc?utm_source=openai)). Thus, careful clinical monitoring for opioid toxicity is essential. Option C is irrelevant (no QTc risk), B is false (no monitoring not acceptable), D is inadequate, and E is impractical and unsupported by guidance. Apply this conclusion only to the clinical circumstances stated, with appropriate specialist review, contraindication checks, shared decision-making and follow-up. Reassess if the physiology, treatment response or competing risk changes. The competing options would require a different haemodynamic profile, diagnosis, procedural indication or risk balance from the one described here.

Reference: SmPC for Alfentanil (EMC) – free fraction increased in renal failure (c. 3 years ago); Scottish Palliative Care Guidelines: alfentanil indications and need for monitoring (recent): https://bnf.nice.org.uk/

Alfentanil Protein Binding in Uraemia — SCE Palliative Medicine MCQ

A patient with severe renal failure (eGFR 8 ml/min) requires opioid analgesia via a continuous subcutaneous infusion (CSCI), and alfentanil is chosen. Which of the following monitoring strategies is most important in this setting?

A patient with severe renal failure (eGFR 8 ml/min) requires opioid analgesia via a continuous subcutaneous infusion (CSCI), and alfentanil is chosen. Which of the following monitoring strategies is most important in this setting?